



DH CIRCULAR No: 549/2012
DH 4221/2012

17th December 2012

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Exemestane 25mg Tablets

Exemestane 25mg tablets have been recommended by the Government Formulary List Advisory Committee and approved by the Superintendent of Public Health for introduction onto the Government Formulary List.

Exemestane is a steroidal aromatase inhibitor indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer, following 2 to 3 years of initial adjuvant tamoxifen therapy; and for the treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.

The recommended dose is 25mg orally once daily, preferably taken after a meal.

Consultant oncologist can prescribe Exemestane 25mg tablets as a last resort after treatment with the non-steroidal aromatase inhibitors, anastrozole/ letrozole, upon disease progression, as per licensed indications.

Exemestane 25mg tablets are protocol- regulated with protocol number 64 (attached).

Exemestane 25mg tablets have been procured through the Central Procurement and Supplies Unit and are now available for use as per protocol.

Dr Natasha Azzopardi Muscat
Chief Medical Officer

Exemestane 25mg Tablets

Prescriber Criteria: Consultant Oncologist

Out-Patient and In-Patient Use:

1. Malignancy

To be used as a last resort after treatment with the non-steroidal aromatase inhibitors, anastrozole/ letrozole, upon disease progression for the:

- Adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer, following 2-3 years of initial adjuvant tamoxifen therapy;
- Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following anti-oestrogen therapy.

Duration of Approval:

1 year